About BioLife Solutions, Inc. - Common Stock (BLFS)
Biolife Solutions is a biotechnology company that specializes in the development and commercialization of innovative biopreservation products and services designed to improve the storage and transportation of cells, tissues, and organs. The company focuses on providing high-quality, cost-effective solutions that enhance the viability and functionality of biological samples, crucial for advancements in regenerative medicine, cell therapy, and clinical applications. By leveraging its proprietary technologies, Biolife Solutions aims to support the growing demand for safe and efficient biobanking and biopreservation practices across the healthcare and pharmaceutical sectors. Read More
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock.
